SCIENTIFIC CONFERENCE ON THE FAILING HEART

我们计划于1999年8月18日至22日在犹他州盐湖城的雪鸟会议中心举行第三届美国心脏协会(AHA)“心力衰竭”会议，题为“治疗心力衰竭的分子、细胞和综合生理学方法科学会议”。本次会议由AHA的流通和基础科学委员会主办。此前的两次“心力衰竭”会议分别于1993年和1996年在加利福尼亚州阿西洛默和盐湖城成功举办。会议描述-随着转基因和基因打靶技术的出现以及在小鼠心脏生理学和成像方面取得的进展，心血管科学领域正在迅速转变为一门真正综合了分子生物学、发育生物学、遗传学、形态学、药理学和生理学的科学。这次为期四天的会议包括讲座、讨论、研讨会、海报展示，重点关注心力衰竭研究的新发展，并为受训人员和初级研究人员举办新研究员奖竞赛，为新成立的研究人员举办心血管研究奖竞赛。75位受邀演讲者将在23次全体会议、两次研讨会和三次扩大海报会议上发表演讲。会议形式旨在为与会者在会议和休息期间进行密集互动提供机会。会议目的：L)提供心肌病和心力衰竭分子遗传学研究的最新进展，2)描述与心肌病心脏信号转导改变相关的新的细胞机制，3)综述新的转基因和基因靶向心肌病模型的研究进展，4)讨论利用综合生理学方法探索转基因小鼠模型的新途径，5)讨论通过各种形态和成像方法分析转基因小鼠心脏的方法。预期的参与者-心脏病学家、心血管生理学家、药理学家、细胞生物学家、生物化学家、临床研究人员和其他对心力衰竭感兴趣的科学家被邀请提交摘要以供海报演示。我们将为学员提供75%的注册费折扣，并为提交优秀摘要的学员和初级调查人员提供20个旅费奖励。预计至少有300人参加。

We plan to hold the third American Heart Association (AHA) "Failing Heart" Conference entitled "Scientific Conference on Molecular, Cellular, and Integrated Physiological Approaches to the Failing Heart" on August 18-22, 1999 at Snowbird Conference Center in Salt Lake City, Utah. This conference is sponsored by the AHA's Councils on Circulation and Basic Science. Two previous "Failing Heart" conferences were held quite successfully in Asilomer, CA in 1993 and in Salt Lake City in 1996. Conference Description - With the advent of transgenic and gene- targeting technologies as well as the progress made in murine cardiac physiology and imaging, the field of cardiovascular science is rapidly transforming into a truly integrated science of molecular biology, developmental biology, genetics, morphology, pharmacology, and physiology. This four-day conference includes lectures, discussion, workshops, poster presentations focusing on new development on heart failure research, and hosts a New Investigator Award competition for trainees and junior investigators and Cardiovascular Research Prize Competition for newly established investigators. Seventy-five (75) invited speakers will give presentations at 23 plenary sessions, two workshops, and three extended poster sessions. The meeting format is designed to provide opportunity for intense interaction among participants during the sessions and breaks. Conference Objectives - The purpose of the conference is to l) provide an update regarding the advances in molecular genetics of cardiomyopathy and cardiac failure, 2) characterize new cellular mechanisms associated with altered signal transduction in myopathic hearts, 3) review advances with respect to new transgenic and gene targeted models of cardiomyopathy, 4) discuss new ways to explore transgenic murine models using integrated physiological approaches, and 5) discuss ways to analyze transgenic mouse hearts by various morphological and imaging approaches. Anticipated Participants - Cardiologists, cardiovascular physiologists, pharmacologists, cell biologists, biochemists, clinical investigators, and other scientists interested in heart failure are invited to submit an abstract for poster presentation. We will discount the registration fee by 75% for trainees and 20 travel awards will be provided for trainees and junior investigators submitting outstanding abstracts. At least 300 participants are expected.